US4525EP1011
© EQS Newswire
26.11.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
News Preview
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
NEW YORK, November 26, 2025 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of......
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
News Preview
NEW YORK, Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Key Data Highlighting Vidofludimus Calcium’s Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS –
– Phase 2 CALLIPER Data Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Progressive Multiple ......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
29.10.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Industry and Investor Conferences in November
News Preview
Immunic to Participate in Industry and Investor Conferences in November
NEW YORK, October 29, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and inve......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
29.10.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Industry and Investor Conferences in November
News Preview
NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in Novemb...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.10.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Scientific and Investor Conferences in October
News Preview
Immunic to Participate in Scientific and Investor Conferences in October
NEW YORK, October 1, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and in......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.09.2025
IMUX
LISTED
NASDAQ
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
News Preview
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over Placebo in the Over......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.09.2025
IMUX
LISTED
NASDAQ
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
News Preview
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –
– Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Further –
NE......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.09.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Investor and Scientific Conferences in September
News Preview
Immunic to Participate in Investor and Scientific Conferences in September
NEW YORK, September 4, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and ......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes, Reinforcing the Drug’s Neuroprotective Potential and Ability to Slow ......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
IMUX
LISTED
NASDAQ
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
News Preview
Immunic Reports New, Positive Long-Term Open-Label Extension Data
From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW –
– Vidofludimus Calcium Continues to Demonstrate ......
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
IMUX
LISTED
NASDAQ
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
News Preview
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW –
– Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years –
NEW YORK, June 24, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
05.06.2025
IMUX
LISTED
NASDAQ
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
News Preview
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 –
– Addi......
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
IMUX
LISTED
NASDAQ
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
News Preview
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 –
– Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprot...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
News Preview
NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-...
Themefolio
Profiler
Peergroup
© EQS Newswire
02.06.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Investor, Scientific and Industry Conferences in June
News Preview
Immunic to Participate in Investor, Scientific and Industry Conferences in June
NEW YORK, June 2, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, sc......
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Investor, Scientific and Industry Conferences in June
News Preview
NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June:
June 3-5: Jefferies Hea...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
News Preview
NEW YORK, May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to pur...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Proposed Public Offering
News Preview
NEW YORK, May 28, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants...
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Scientific and Industry Conferences in May
News Preview
Immunic to Participate in Scientific and Industry Conferences in May
NEW YORK, May 2, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry ......
Themefolio
Profiler
Peergroup
© PR Newswire
02.05.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Scientific and Industry Conferences in May
News Preview
NEW YORK, May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May:
May 3-6: Digestive Disease Week (DD...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.04.2025
IMUX
LISTED
NASDAQ
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
News Preview
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Popul......
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
IMUX
LISTED
NASDAQ
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
News Preview
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –
– Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baselin...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
News Preview
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
NEW YORK, April 10, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune di......
Themefolio
Profiler
Peergroup
© PR Newswire
10.04.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
News Preview
NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,66...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.04.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
News Preview
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
NEW YORK, April 9, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune dis......
Themefolio
Profiler
Peergroup
© PR Newswire
09.04.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
News Preview
NEW YORK, April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common s...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.04.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
News Preview
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
NEW YORK, April 1, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and ......
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
IMUX
LISTED
NASDAQ
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
News Preview
NEW YORK, April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April:
April 5-9: American Academy of...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.03.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Scientific and Investor Conferences in March
News Preview
Immunic to Participate in Scientific and Investor Conferences in March
NEW YORK, March 3, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and inve......
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Scientific and Investor Conferences in March
News Preview
NEW YORK, March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:
March 4-7: 34th Annual Meeting...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.02.2025
IMUX
LISTED
NASDAQ
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
News Preview
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
– Vidofludimus Calcium’s Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models –
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus ......
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
IMUX
LISTED
NASDAQ
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
News Preview
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models –
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq:...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.02.2025
IMUX
LISTED
NASDAQ
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
News Preview
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –
– Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc A......
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
IMUX
LISTED
NASDAQ
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
News Preview
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –
– Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinical Trial in Celiac Disease –
– Dose-Dependent Reduction of Body Weight Gain and Food Consumption Observed i...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.02.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Investor and Scientific Conferences in February
News Preview
Immunic to Participate in Investor and Scientific Conferences in February
NEW YORK, February 4, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and s......
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
IMUX
LISTED
NASDAQ
Immunic to Participate in Investor and Scientific Conferences in February
News Preview
NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:
February 10-11: BIO CEO &...
Themefolio
Profiler
Peergroup
© EQS Newswire
07.01.2025
IMUX
LISTED
NASDAQ
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
News Preview
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on......
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
IMUX
LISTED
NASDAQ
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
News Preview
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team an...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.11.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. to Participate in Investor Conference in December
News Preview
Immunic, Inc. to Participate in Investor Conference in December
NEW YORK, November 26, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Im......
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. to Participate in Investor Conference in December
News Preview
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursda...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.11.2024
IMUX
LISTED
NASDAQ
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
News Preview
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
– Includes Phase 1 Data in Healthy Human Subjects and
Phase 1b Data in Celiac Disease Patients –
NEW YORK, November 13, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developi......
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
IMUX
LISTED
NASDAQ
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
News Preview
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients –
NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the da...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.11.2024
IMUX
LISTED
NASDAQ
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
News Preview
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer, will present a company overview at the Q4 Investor Su...
Themefolio
Profiler
Peergroup
© EQS Newswire
07.11.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Immunic, Inc. Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned –
– Ongoing, Twin Phase 3 ENSURE Trials ......
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned –
– Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Scleros...
Themefolio
Profiler
Peergroup
© EQS Newswire
31.10.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
News Preview
Immunic, Inc. to Announce Financial Results for the Third Quarter EndedSeptember 30, 2024, and Provide Corporate Update
– Webcast to be Held at 8:00 am ET on November 7, 2024 –
NEW YORK, October 31, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chro......
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
News Preview
– Webcast to be Held at 8:00 am ET on November 7, 2024 –
NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2024
IMUX
LISTED
NASDAQ
Immunic to Participate in Industry, Scientific and Investor Conferences in November
News Preview
Immunic to Participate in Industry, Scientific and Investor Conferences in November
NEW YORK, October 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following indus......
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
IMUX
LISTED
NASDAQ
Immunic to Participate in Industry, Scientific and Investor Conferences in November
News Preview
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November:
November 4-6: BIO-...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.10.2024
IMUX
LISTED
NASDAQ
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
News Preview
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met –
– IDMC Also Recommended Continuing Trial without Change......
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2024
IMUX
LISTED
NASDAQ
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
News Preview
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met –
– IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing –
– ENSURE Program Remains on Track to be Completed in 2026 –
– Webcast to be Held Today, Oct...
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2024
IMUX
LISTED
NASDAQ
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
News Preview
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2024
IMUX
LISTED
NASDAQ
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
News Preview
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P......
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2024
IMUX
LISTED
NASDAQ
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
News Preview
– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes –
– Clinical Signal Shown for Vidofludimus Calcium on Post COVID Fatigue May Be Related to Epstein-Ba...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.09.2024
IMUX
LISTED
NASDAQ
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
News Preview
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic –
– In Addition to Post COVID Rea......
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
IMUX
LISTED
NASDAQ
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
News Preview
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic –
– In Addition to Post COVID Readouts, Study Designed to Deliver Important Data on the Activity of Vidofludimus Calcium Suppressing Epstein-Barr Virus Reactivation and Related Fatigue...
Themefolio
Profiler
Peergroup
© EQS Newswire
28.08.2024
IMUX
LISTED
NASDAQ
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
News Preview
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that t......
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
IMUX
LISTED
NASDAQ
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
News Preview
NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
IMUX
LISTED
NASDAQ
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President –
– Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceuti......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
